Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 441

1.

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.

Efficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, Groenvold M, Caocci G, Lo Coco F, Gaidano G, Niscola P, Baccarani M, Rosti G, Venditti A, Angelucci E, Fazi P, Vignetti M, Giesinger J.

Value Health. 2019 Nov;22(11):1303-1310. doi: 10.1016/j.jval.2019.06.004. Epub 2019 Aug 7.

PMID:
31708068
2.

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F.

Leukemia. 2019 Oct 14. doi: 10.1038/s41375-019-0589-3. [Epub ahead of print] No abstract available.

PMID:
31611624
3.

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.

Faraoni I, Consalvo MI, Aloisio F, Fabiani E, Giansanti M, Di Cristino F, Falconi G, Tentori L, Di Veroli A, Curzi P, Maurillo L, Niscola P, Lo-Coco F, Graziani G, Voso MT.

Cancers (Basel). 2019 Sep 16;11(9). pii: E1373. doi: 10.3390/cancers11091373.

4.

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.

Mazzarella L, Botteri E, Matthews A, Gatti E, Di Salvatore D, Bagnardi V, Breccia M, Montesinos P, Bernal T, Gil C, Ley TJ, Sanz M, Bhaskaran K, Lo Coco F, Pelicci PG.

Haematologica. 2019 Sep 12. pii: haematol.2019.223925. doi: 10.3324/haematol.2019.223925. [Epub ahead of print]

5.

MRD in AML: The Role of New Techniques.

Voso MT, Ottone T, Lavorgna S, Venditti A, Maurillo L, Lo-Coco F, Buccisano F.

Front Oncol. 2019 Jul 23;9:655. doi: 10.3389/fonc.2019.00655. eCollection 2019. Review.

6.

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.

Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S.

Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.

PMID:
31395600
7.

Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.

Falconi G, Fabiani E, Criscuolo M, Fianchi L, Finelli C, Cerqui E, Pelosi E, Screnci M, Gurnari C, Zangrilli I, Postorino M, Laurenti L, Piciocchi A, Testa U, Lo-Coco F, Voso MT.

Leuk Res. 2019 Sep;84:106191. doi: 10.1016/j.leukres.2019.106191. Epub 2019 Jul 19.

PMID:
31386932
8.

Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.

Iaccarino L, Ottone T, Alfonso V, Cicconi L, Divona M, Lavorgna S, Travaglini S, Ferrantini A, Falconi G, Baer C, Usai M, Forghieri F, Venditti A, Del Principe MI, Arcese W, Voso MT, Haferlach T, Lo-Coco F.

Am J Hematol. 2019 Oct;94(10):1091-1097. doi: 10.1002/ajh.25573. Epub 2019 Jul 23.

PMID:
31292998
9.

Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia.

Lucena-Araujo AR, Coelho-Silva JL, Pereira-Martins DA, Silveira DR, Koury LC, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria AB, Kerbauy F, de Lourdes Chauffaille M, Bendit I, Rocha V, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk PJM, Lo-Coco F, Sanz MA, Berliner N, Rego EM.

Blood. 2019 Sep 19;134(12):951-959. doi: 10.1182/blood.2019000239. Epub 2019 Jul 10.

PMID:
31292112
10.

The simpler, the better: oral arsenic for acute promyelocytic leukemia.

Zhu HH, Hu J, Lo-Coco F, Jin J.

Blood. 2019 Aug 15;134(7):597-605. doi: 10.1182/blood.2019000760. Epub 2019 May 21. Review.

PMID:
31113776
11.

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations.

Mariotti B, Meconi F, Palmieri R, De Bellis E, Lavorgna S, Ottone T, Martini V, Lo-Coco F, Cicconi L.

Case Rep Hematol. 2019 Apr 11;2019:6707506. doi: 10.1155/2019/6707506. eCollection 2019.

12.

Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.

Faraoni I, Giansanti M, Voso MT, Lo-Coco F, Graziani G.

Biochem Pharmacol. 2019 Sep;167:133-148. doi: 10.1016/j.bcp.2019.04.019. Epub 2019 Apr 24. Review.

PMID:
31028744
13.

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.

Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, Pandolfi PP.

Cell Res. 2019 Jun;29(6):446-459. doi: 10.1038/s41422-019-0162-7. Epub 2019 Apr 25.

PMID:
31024166
14.

Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations.

Gurnari C, Lombardi AM, Cosi E, Biagetti G, Buccisano F, Franceschini L, Di Veroli A, Falconi G, Fabiani E, Cantonetti M, Nasso D, Lo-Coco F, Randi ML, Voso MT.

Br J Haematol. 2019 Aug;186(4):e100-e103. doi: 10.1111/bjh.15931. Epub 2019 Apr 23. No abstract available.

PMID:
31016714
15.

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F.

Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Review.

16.

Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.

Alfonso V, Iaccarino L, Ottone T, Cicconi L, Lavorgna S, Divona M, Cairoli R, Cristiano A, Ciardi C, Travaglini S, Falconi G, Hasan SK, Venditti A, Arcese W, Voso MT, Lo-Coco F.

Leukemia. 2019 Jun;33(6):1527-1530. doi: 10.1038/s41375-018-0298-3. Epub 2019 Jan 16. No abstract available.

PMID:
30651632
17.

Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931- July 15, 2018.

Amadori S, Arcese W, Avvisati G, Gale RP, Lo-Coco F.

Leukemia. 2019 Feb;33(2):285-286. doi: 10.1038/s41375-018-0352-1. No abstract available.

18.

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.

Piedimonte M, Ottone T, Alfonso V, Ferrari A, Conte E, Divona M, Bianchi MP, Ricciardi MR, Mirabilii S, Licchetta R, Campagna A, Cicconi L, Galassi G, Pelliccia S, Leporace A, Lo Coco F, Tafuri A.

BMC Cancer. 2019 Jan 10;19(1):50. doi: 10.1186/s12885-019-5265-5. Review.

19.

Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.

Efficace F, Breccia M, Avvisati G, Cottone F, Intermesoli T, Borlenghi E, Carluccio P, Rodeghiero F, Fabbiano F, Luppi M, Romani C, Sborgia M, D'Ardia S, Nobile F, Cantore N, Crugnola M, Nadali G, Vignetti M, Amadori S, Lo Coco F.

Leukemia. 2019 Jul;33(7):1598-1607. doi: 10.1038/s41375-018-0325-4. Epub 2018 Dec 20.

PMID:
30573776
20.

PML/RARA inhibits expression of HSP90 and its target AKT.

Piredda ML, Gaur G, Catalano G, Divona M, Banella C, Travaglini S, Puzzangara MC, Voso MT, Lo-Coco F, Noguera NI.

Br J Haematol. 2019 Mar;184(6):937-948. doi: 10.1111/bjh.15715. Epub 2018 Dec 9.

PMID:
30536958
21.

Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome.

Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, Zizzari A, De Angelis G, Fraboni D, Divona M, Voso MT, Sconocchia G, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Semin Hematol. 2018 Oct;55(4):209-214. doi: 10.1053/j.seminhematol.2018.02.006. Epub 2018 Feb 21. Review.

PMID:
30502849
22.

Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia.

Iaccarino L, Divona M, Ottone T, Cicconi L, Lavorgna S, Ciardi C, Alfonso V, Travaglini S, Facchini L, Cimino G, Di Bona E, Voso MT, Lo-Coco F.

Genes Chromosomes Cancer. 2019 Jan;58(1):60-65. doi: 10.1002/gcc.22708. Epub 2018 Dec 4.

PMID:
30421475
23.

Molecular Expression of Bone Marrow Angiogenic Factors, Cell-Cell Adhesion Molecules and Matrix-Metallo-Proteinases in Plasmacellular Disorders: a Molecular Panel to İnvestigate Disease Progression.

Rapanotti MC, Franceschini L, Viguria TMS, Ialongo C, Fraboni D, Cerretti R, De Angelis G, Pupo L, Rizzo M, Cantonetti M, Postorino M, Voso MT, Lo-Coco F.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018059. doi: 10.4084/MJHID.2018.059. eCollection 2018. No abstract available.

24.

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT.

Br J Haematol. 2019 Jun;185(5):954-957. doi: 10.1111/bjh.15655. Epub 2018 Nov 8. No abstract available.

PMID:
30407614
25.

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.

Falconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Lindfors Rossi EL, Finelli C, Cerqui E, Ottone T, Molteni A, Parma M, Santarone S, Candoni A, Sica S, Leone G, Lo-Coco F, Voso MT.

Leukemia. 2019 Mar;33(3):785-790. doi: 10.1038/s41375-018-0284-9. Epub 2018 Oct 5. No abstract available.

26.

Prof. Franco Mandelli: Leukaemia therapy pioneer.

Gale RP, Lo-Coco F.

Bone Marrow Transplant. 2018 Nov;53(11):1375-1376. doi: 10.1038/s41409-018-0348-5. Epub 2018 Oct 2. No abstract available.

PMID:
30279574
27.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS).

Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. No abstract available.

PMID:
30029156
28.

Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.

Strocchio L, Gurnari C, Santoro N, Putti MC, Micalizzi C, Zecca M, Cuccurullo R, Girardi K, Diverio D, Testi AM, Lo-Coco F, Locatelli F.

Br J Haematol. 2019 Apr;185(2):360-363. doi: 10.1111/bjh.15507. Epub 2018 Jul 20. No abstract available.

PMID:
30028005
29.

Molecular remission as a therapeutic objective in acute promyelocytic leukemia.

Cicconi L, Fenaux P, Kantarjian H, Tallman M, Sanz MA, Lo-Coco F.

Leukemia. 2018 Aug;32(8):1671-1678. doi: 10.1038/s41375-018-0219-5. Epub 2018 Jul 19. Review.

PMID:
30026570
30.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.

Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F.

Ann Hematol. 2018 Oct;97(10):1797-1802. doi: 10.1007/s00277-018-3400-z. Epub 2018 Jun 27.

PMID:
29951912
31.

Towards home-based treatment for acute promyelocytic leukaemia, with caution.

Lo-Coco F, Cicconi L.

Lancet Oncol. 2018 Jul;19(7):846-847. doi: 10.1016/S1470-2045(18)30355-3. Epub 2018 Jun 5. No abstract available.

PMID:
29884592
32.

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, van der Werff ten Bosch J, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Foà R, Locatelli F, Kaspers GJL.

Blood. 2018 Jul 26;132(4):405-412. doi: 10.1182/blood-2018-03-836528. Epub 2018 May 22.

PMID:
29789356
33.

Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers.

Efficace F, Cottone F, Sparano F, Lo-Coco F.

Cancer. 2018 Jul 15;124(14):3066-3067. doi: 10.1002/cncr.31521. Epub 2018 Apr 30. No abstract available.

34.

Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes.

Martínez-Losada C, Serrano-López J, Serrano-López J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jérez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibañez M, Sempere A, Sanz MÁ, Lo-Coco F, Sánchez-García J.

Haematologica. 2018 Sep;103(9):e400-e403. doi: 10.3324/haematol.2018.188433. Epub 2018 Apr 5. No abstract available.

35.

The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation.

Faraoni I, Aloisio F, De Gabrieli A, Consalvo MI, Lavorgna S, Voso MT, Lo-Coco F, Graziani G.

Cancer Lett. 2018 Jun 1;423:127-138. doi: 10.1016/j.canlet.2018.03.008. Epub 2018 Mar 8.

PMID:
29526802
36.

Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.

Buccisano F, Maurillo L, Del Principe MI, Di Veroli A, De Bellis E, Biagi A, Zizzari A, Rossi V, Rapisarda V, Amadori S, Voso MT, Lo-Coco F, Arcese W, Venditti A.

Expert Rev Hematol. 2018 Apr;11(4):307-313. doi: 10.1080/17474086.2018.1447378. Epub 2018 Mar 7. Review.

PMID:
29495904
37.

Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia.

Gurnari C, Panetta P, Fabiani E, Nardone AM, Postorivo D, Falconi G, Franceschini L, Rizzo M, Rapisarda VM, De Bellis E, Lo-Coco F, Voso MT.

Mol Clin Oncol. 2018 Mar;8(3):463-465. doi: 10.3892/mco.2017.1543. Epub 2017 Dec 29.

38.

Longitudinal detection of DNMT3AR882H transcripts in patients with acute myeloid leukemia.

Ottone T, Alfonso V, Iaccarino L, Hasan SK, Mancini M, Divona M, Lavorgna S, Cicconi L, Panetta P, Maurillo L, Del Principe MI, Irno Consalvo M, Franceschini L, Angelini DF, Battistini L, Guerrera G, De Bardi M, Fabiani E, Falconi G, Arcese W, Amadori S, Buccisano F, Venditti A, Voso MT, Lo-Coco F.

Am J Hematol. 2018 May;93(5):E120-E123. doi: 10.1002/ajh.25061. Epub 2018 Feb 24. No abstract available.

39.

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Franca-Neto PL, Coelho-Silva JL, de Deus Wagatsuma VM, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Chiattone CS, Fagundes EM, Chauffaille ML, Schrier SL, Tallman MS, Ribeiro RC, Grimwade D, Ganser A, Löwenberg B, Lo-Coco F, Sanz MA, Berliner N, Rego EM.

Blood Adv. 2017 Sep 15;1(21):1807-1814. doi: 10.1182/bloodadvances.2017005926. eCollection 2017 Sep 26.

40.

Progress and criticalities in the management of acute promyelocytic leukemia.

Lo-Coco F, Cicconi L, Voso MT.

Oncotarget. 2017 Nov 12;8(59):99221-99222. doi: 10.18632/oncotarget.22385. eCollection 2017 Nov 21. No abstract available.

41.

The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia.

Fabiani E, Falconi G, Noguera NI, Saulle E, Cicconi L, Divona M, Banella C, Picardi A, Cerio AM, Boe L, Sanchez M, Pelosi E, Testa U, Lo-Coco F, Voso MT.

Oncotarget. 2017 Sep 20;8(48):84074-84085. doi: 10.18632/oncotarget.21101. eCollection 2017 Oct 13.

42.

Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation.

Mastrangelo D, Pelosi E, Castelli G, Lo-Coco F, Testa U.

Blood Cells Mol Dis. 2018 Mar;69:57-64. doi: 10.1016/j.bcmd.2017.09.005. Epub 2017 Sep 21. Review.

PMID:
28954710
43.

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Iaccarino L, Ottone T, Hasan SK, Divona M, Cicconi L, Lavorgna S, Alfonso V, Basso G, Barragán E, Bocchia M, Rego EM, Grimwade D, Voso MT, Lo-Coco F.

Leuk Lymphoma. 2018 May;59(5):1268-1270. doi: 10.1080/10428194.2017.1369067. Epub 2017 Aug 24. No abstract available.

PMID:
28838264
44.

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.

Masciarelli S, Capuano E, Ottone T, Divona M, De Panfilis S, Banella C, Noguera NI, Picardi A, Fontemaggi G, Blandino G, Lo-Coco F, Fazi F.

Leukemia. 2018 Feb;32(2):285-294. doi: 10.1038/leu.2017.231. Epub 2017 Aug 4.

45.

Treatment of Low-Blast Count AML using Hypomethylating Agents.

De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Review.

46.

Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?

Efficace F, Gaidano G, Lo-Coco F.

Blood. 2017 Aug 17;130(7):859-866. doi: 10.1182/blood-2017-03-737403. Epub 2017 Jul 10. Review.

PMID:
28694324
47.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.

N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.

48.

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.

Abla O, Ribeiro RC, Testi AM, Montesinos P, Creutzig U, Sung L, Di Giuseppe G, Stephens D, Feusner JH, Powell BL, Hasle H, Kaspers GJL, Dalla-Pozza L, Lassaletta A, Tallman MS, Locatelli F, Reinhardt D, Lo-Coco F, Hitzler J, Sanz MA.

Ann Hematol. 2017 Sep;96(9):1449-1456. doi: 10.1007/s00277-017-3042-6. Epub 2017 Jun 8.

PMID:
28597167
49.

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.

Noguera NI, Pelosi E, Angelini DF, Piredda ML, Guerrera G, Piras E, Battistini L, Massai L, Berardi A, Catalano G, Cicconi L, Castelli G, D'Angiò A, Pasquini L, Graziani G, Fioritoni G, Voso MT, Mastrangelo D, Testa U, Lo-Coco F.

Oncotarget. 2017 May 16;8(20):32550-32565. doi: 10.18632/oncotarget.15925.

50.

Clonal evolution in therapy-related neoplasms.

Fabiani E, Falconi G, Fianchi L, Criscuolo M, Ottone T, Cicconi L, Hohaus S, Sica S, Postorino M, Neri A, Lionetti M, Leone G, Lo-Coco F, Voso MT.

Oncotarget. 2017 Feb 14;8(7):12031-12040. doi: 10.18632/oncotarget.14509.

Supplemental Content

Loading ...
Support Center